Εμφάνιση απλής εγγραφής

dc.creatorDalekos G.N., Stefos A., Georgiadou S., Lygoura V., Michail A., Ntaios G., Samakidou A., Giannoulis G., Gabeta S., Vlychou M., Petinaki E., Leventogiannis K., Giamarellos-Bourboulis E.J., Gatselis N.K.en
dc.date.accessioned2023-01-31T07:49:23Z
dc.date.available2023-01-31T07:49:23Z
dc.date.issued2021
dc.identifier10.1016/j.ejim.2021.03.026
dc.identifier.issn09536205
dc.identifier.urihttp://hdl.handle.net/11615/73017
dc.description.abstractAims Infection by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) may lead to the development of severe respiratory failure. In hospitalized-patients, prompt interruption of the virus-driven inflammatory process by using combination treatments seems theoretically of outmost importance. Our aim was to investigate the hypothesis of multifaceted management of these patients. Methods A treatment algorithm based on ferritin was applied in 311 patients (67.2% males; median age 63-years; moderate disease, n=101; severe, n=210). Patients with ferritin <500ng/ml received anakinra 2-4mg/kg/day ± corticosteroids (Arm A, n=142) while those with ≥500ng/ml received anakinra 5-8mg/kg/day with corticosteroids and γ-globulins (Arm B, n=169). In case of no improvement a single dose of tocilizumab (8mg/kg; maximum 800mg) was administered with the potential of additional second and/or third pulses. Treatment endpoints were the rate of the development of respiratory failure necessitating intubation and the SARS-CoV-2-related mortality. The proposed algorithm was also validated in matched hospitalized-patients treated with standard-of-care during the same period. Results In overall, intubation and mortality rates were 5.8% and 5.1% (0% in moderate; 8.6% and 7.6% in severe). Low baseline pO2/FiO2 and older age were independent risk factors. Comparators had significantly higher intubation (HR=7.4; 95%CI: 4.1-13.4; p<0.001) and death rates (HR=4.5, 95%CI: 2.1-9.4, p<0.001). Significant adverse events were rare, including severe secondary infections in only 7/311 (2.3%). Conclusions Early administration of personalized combinations of immunomodulatory agents may be life-saving in hospitalized-patients with COVID-19. An immediate intervention (the sooner the better) could be helpful to avoid development of full-blown acute respiratory distress syndrome and improve survival. © 2021en
dc.language.isoenen
dc.sourceEuropean Journal of Internal Medicineen
dc.source.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85103700786&doi=10.1016%2fj.ejim.2021.03.026&partnerID=40&md5=9c1031becf611698b3fe4bc80cf3d9dc
dc.subjectalanine aminotransferaseen
dc.subjectanakinraen
dc.subjectantibiotic agenten
dc.subjectC reactive proteinen
dc.subjectD dimeren
dc.subjectdexamethasoneen
dc.subjectenoxaparinen
dc.subjectferritinen
dc.subjectgranulocyte colony stimulating factoren
dc.subjecthydrocortisoneen
dc.subjectimmunoglobulinen
dc.subjectlactate dehydrogenaseen
dc.subjectmethylprednisoloneen
dc.subjectremdesiviren
dc.subjecttocilizumaben
dc.subjectinterleukin 1 receptor blocking agenten
dc.subjectadulten
dc.subjectadult respiratory distress syndromeen
dc.subjectalanine aminotransferase levelen
dc.subjectalgorithmen
dc.subjectanasarcaen
dc.subjectArticleen
dc.subjectbacteremiaen
dc.subjectbacterial pneumoniaen
dc.subjectbloodstream infectionen
dc.subjectbreathing rateen
dc.subjectCandidaen
dc.subjectcatheter infectionen
dc.subjectchronic obstructive lung diseaseen
dc.subjectcombination drug therapyen
dc.subjectcomorbidityen
dc.subjectcomputer assisted tomographyen
dc.subjectcontrolled studyen
dc.subjectcoronary artery diseaseen
dc.subjectcoronavirus disease 2019en
dc.subjectCOVID-19 testingen
dc.subjectdiabetes mellitusen
dc.subjectdisease durationen
dc.subjectdisease severityen
dc.subjectdrug half lifeen
dc.subjectdrug megadoseen
dc.subjectdrug pulse therapyen
dc.subjectdrug withdrawalen
dc.subjectfemaleen
dc.subjectferritin blood levelen
dc.subjectfollow upen
dc.subjectfraction of inspired oxygenen
dc.subjectheart failureen
dc.subjecthematomaen
dc.subjecthospital admissionen
dc.subjecthospital infectionen
dc.subjecthospital patienten
dc.subjecthospitalizationen
dc.subjecthumanen
dc.subjecthypertensionen
dc.subjectimmunotherapyen
dc.subjectinjection site reactionen
dc.subjectintubationen
dc.subjectKolmogorov Smirnov testen
dc.subjectlactate dehydrogenase blood levelen
dc.subjectleukocyte counten
dc.subjectlower respiratory tract infectionen
dc.subjectlung embolismen
dc.subjectlung infiltrateen
dc.subjectlymphocyte counten
dc.subjectlymphocytopeniaen
dc.subjectmajor clinical studyen
dc.subjectmaleen
dc.subjectmesenteric vein thrombosisen
dc.subjectmortality rateen
dc.subjectnasopharyngeal swaben
dc.subjectneutropeniaen
dc.subjectneutrophil counten
dc.subjectobesityen
dc.subjectobservational studyen
dc.subjectosteoporosisen
dc.subjectoxygen saturationen
dc.subjectoxygen tensionen
dc.subjectoxygen therapyen
dc.subjectpathophysiologyen
dc.subjectperipheral edemaen
dc.subjectphase 3 clinical trial (topic)en
dc.subjectplatelet counten
dc.subjectpneumoniaen
dc.subjectprospective studyen
dc.subjectpulse oximetryen
dc.subjectrespiratory failureen
dc.subjectrisk factoren
dc.subjectsecondary infectionen
dc.subjectsingle drug doseen
dc.subjectStenotrophomonas maltophiliaen
dc.subjectthorax radiographyen
dc.subjectthrombocytopeniaen
dc.subjecttreatment contraindicationen
dc.subjecttreatment durationen
dc.subjecttreatment outcomeen
dc.subjectageden
dc.subjectmiddle ageden
dc.subjectrespiratory distress syndromeen
dc.subjectrespiratory failureen
dc.subjectAgeden
dc.subjectCOVID-19en
dc.subjectFemaleen
dc.subjectHumansen
dc.subjectInterleukin 1 Receptor Antagonist Proteinen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectRespiratory Distress Syndromeen
dc.subjectRespiratory Insufficiencyen
dc.subjectSARS-CoV-2en
dc.subjectTreatment Outcomeen
dc.subjectElsevier B.V.en
dc.titleLessons from pathophysiology: Use of individualized combination treatments with immune interventional agents to tackle severe respiratory failure in patients with COVID-19en
dc.typejournalArticleen


Αρχεία σε αυτό το τεκμήριο

ΑρχείαΜέγεθοςΤύποςΠροβολή

Δεν υπάρχουν αρχεία που να σχετίζονται με αυτό το τεκμήριο.

Αυτό το τεκμήριο εμφανίζεται στις ακόλουθες συλλογές

Εμφάνιση απλής εγγραφής